LivaNova (NASDAQ:LIVN) Coverage Initiated by Analysts at The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of LivaNova (NASDAQ:LIVN) in a research note released on Friday, Marketbeat reports. The firm issued a buy rating and a $65.00 price objective on the stock.

Several other equities analysts have also recently weighed in on the company. Needham & Company LLC raised their price target on LivaNova from $72.00 to $75.00 and gave the company a buy rating in a report on Wednesday, July 31st. Baird R W raised shares of LivaNova from a hold rating to a strong-buy rating in a report on Tuesday, September 17th. Stifel Nicolaus upped their price target on shares of LivaNova from $70.00 to $72.00 and gave the company a buy rating in a research note on Thursday, July 25th. Finally, Robert W. Baird upgraded shares of LivaNova from a neutral rating to an outperform rating and increased their price objective for the company from $55.00 to $66.00 in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $69.83.

LivaNova Price Performance

LIVN stock opened at $52.68 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.45. The company’s fifty day moving average price is $48.63 and its 200-day moving average price is $53.39. LivaNova has a one year low of $42.75 and a one year high of $64.47. The company has a market capitalization of $2.85 billion, a PE ratio of -87.80 and a beta of 1.00.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.66 by $0.15. The business had revenue of $318.60 million for the quarter, compared to analysts’ expectations of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. On average, equities analysts anticipate that LivaNova will post 2.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. raised its stake in shares of LivaNova by 204.3% in the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after acquiring an additional 863,157 shares during the period. First Light Asset Management LLC grew its holdings in LivaNova by 591.1% during the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock valued at $38,944,000 after purchasing an additional 607,598 shares during the last quarter. Great Lakes Advisors LLC purchased a new stake in LivaNova in the 2nd quarter worth about $16,614,000. Mesirow Institutional Investment Management Inc. bought a new stake in LivaNova in the first quarter worth about $13,816,000. Finally, Driehaus Capital Management LLC lifted its stake in LivaNova by 64.7% in the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after purchasing an additional 213,749 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.